Cobb Adrienne N, Barkat Adel, Daungjaiboon Witawat, Halandras Pegge, Crisostomo Paul, Kuo Paul C, Aulivola Bernadette
Department of Surgery, Loyola University Medical Center, Maywood, IL; One:MAP Section of Surgical Analytics, Department of Surgery, Loyola University Chicago, Chicago, IL.
Department of Surgery, Loyola University Medical Center, Maywood, IL; Division of Vascular Surgery and Endovascular Therapy, Loyola University Medical Center, Maywood, IL.
Ann Vasc Surg. 2018 Jan;46:54-59. doi: 10.1016/j.avsg.2017.06.149. Epub 2017 Jul 8.
Carotid body tumors (CBTs) are rare entities for which surgical resection remains the gold standard. Given their hypervascularity, preoperative embolization is often used; however, controversy exists over whether a benefit is associated. Proponents of embolization argue that it minimizes blood loss and complications. Critics argue that cost and stroke outweigh benefits. This study aimed to investigate the impact of embolization on outcomes following CBT resection.
Patients undergoing CBT resection were identified using the Healthcare Cost and Utilization Project State Inpatient Database for 5 states between 2006 and 2013. Patients were divided into 2 groups: carotid body tumor resection alone (CBTR) and carotid body tumor resection with preoperative arterial embolization (CBETR). Descriptive statistics were calculated using arithmetic means with standard deviations for continuous variables and proportions for categorical variables. Patients were propensity score matched on the basis of sex, age, race, insurance, and comorbidity prior to analysis. Risk-adjusted odds of mortality, stroke, nerve injury, blood loss, and length of stay (LOS) were calculated using mixed-effects regression models with fixed effects for age, race, sex, and comorbidities.
A total of 547 patients were identified. Of these, 472 patients underwent CBTR and 75 underwent CBETR. Mean age was 54.7 ± 16 years. Mean number of days between embolization and resection was 0.65 ± 0.72 days (range 0-3). When compared with CBTR, there were no significant differences in mortality for CBETR (1.35% vs. 0%, P = 0.316), cranial nerve injury (2.7% vs. 0%, P = 0.48), and blood loss (2.7% vs. 6.8%, P = 0.245). Following risk adjustment, CBETR increased the odds of prolonged LOS (odds ratio 5.3, 95% confidence interval 2.1-13.3).
CBT resection is a relatively rare procedure. The utility of preoperative tumor embolization has been questioned. This study demonstrates no benefit of preoperative tumor embolization.
颈动脉体瘤(CBTs)是罕见的疾病,手术切除仍是其金标准。鉴于其血管丰富,术前常采用栓塞术;然而,对于栓塞术是否有益存在争议。栓塞术的支持者认为,它能将失血和并发症降至最低。批评者则认为,成本和中风的风险超过了益处。本研究旨在调查栓塞术对CBT切除术后结果的影响。
利用2006年至2013年间5个州的医疗成本和利用项目州住院数据库,确定接受CBT切除的患者。患者分为两组:单纯颈动脉体瘤切除术(CBTR)和术前动脉栓塞的颈动脉体瘤切除术(CBETR)。连续变量使用算术平均数和标准差进行描述性统计,分类变量使用比例进行描述性统计。在分析之前,根据性别、年龄、种族、保险和合并症对患者进行倾向评分匹配。使用混合效应回归模型计算调整风险后的死亡率、中风、神经损伤、失血和住院时间(LOS)的比值比,年龄、种族、性别和合并症为固定效应。
共确定了547例患者。其中,472例患者接受了CBTR,75例接受了CBETR。平均年龄为54.7±16岁。栓塞与切除之间的平均天数为0.65±0.72天(范围0-3天)。与CBTR相比,CBETR在死亡率(1.35%对0%,P=0.316)、颅神经损伤(2.7%对0%,P=0.48)和失血(2.7%对6.8%,P=0.245)方面无显著差异。经过风险调整后,CBETR增加了住院时间延长的几率(比值比5.3,95%置信区间2.1-13.3)。
CBT切除是一种相对罕见的手术。术前肿瘤栓塞的效用受到质疑。本研究表明术前肿瘤栓塞没有益处。